Tune Therapeutics receives $40M funding. It aims to tune the activity of genes within cells.Tune CEO Matt Kane. (Tune Photo)A new biotech startup with operations in Seattle and Durham, N.C., has launched with $40 million in new funding and a#Business Technology·chieftechnologyofficer.blog·Dec 8, 2021Tune Therapeutics receives $40M funding. It aims to tune the activity of genes within cells.